Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00551616 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception
A Phase 3 study, sponsored by HRA Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,221
- Enrollment target
NCT00551616 is a Phase 3 study that has completed, run by HRA Pharma. The registered enrollment target is 2,221 participants.
The verdict
NCT00551616, a Phase 3 study, has completed, sponsored by HRA Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,221 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.
Interventions
- DRUG CDB-2914
- DRUG Levonorgestrel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,221 participants |
| Start Date | 2007-04 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00551616
The ClinicalTrials.gov registry entry for NCT00551616 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 2,221 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is HRA Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CDB-2914 is the first listed.
NCT00551616 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00551616 about?
NCT00551616 is a clinical study titled "Safety and Efficacy of CDB-2914 in Comparison to Levonorgestrel for Emergency Contraception". The purpose of this study is to assess the safety and efficacy of CDB-2914 in comparison to levonorgestrel for preventing pregnancy up to 5 days after unprotected sexual intercourse.
What is the current status of trial NCT00551616?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,221 participants. The study started on 2007-04. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00551616?
The interventions under investigation include: CDB-2914 (DRUG), Levonorgestrel (DRUG).
Who is sponsoring clinical trial NCT00551616?
This trial is sponsored by HRA Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.